Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]]
Latest Information Update: 07 Jun 2012
At a glance
- Drugs Canfosfamide (Primary) ; Carboplatin (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASSIST-3
- 08 Jan 2007 Media release 9071069.
- 08 Jan 2007 Status change
- 29 Nov 2005 New trial record.